After a median follow-up of 12 months [ IQR 10-21 ] ) and 161 ( 96 % ) deaths ( 80 in the docetaxel group , 81 in the active symptom control group ) , median overall survival in the docetaxel group was 5.2 months ( 95 % CI 4.1-5 .9 ) versus 3.6 months ( 3.3-4 .4 ) in the active symptom control group ( hazard ratio 0.67 , 95 % CI 0.49-0 .92 ; p = 0.01 ) .